复星医药
(600196)
| 流通市值：498.27亿 | | | 总市值：628.30亿 |
| 流通股本：21.18亿 | | | 总股本：26.71亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 9,420,322,797.34 | 41,067,195,862.59 | 30,911,889,002.9 | 20,462,812,731.15 |
| 营业收入 | 9,420,322,797.34 | 41,067,195,862.59 | 30,911,889,002.9 | 20,462,812,731.15 |
| 二、营业总成本 | 9,130,342,151.68 | 39,397,511,520.64 | 29,362,812,762.85 | 19,408,879,676.26 |
| 营业成本 | 4,920,296,039.59 | 21,365,573,972.4 | 15,889,599,601.5 | 10,463,385,539.56 |
| 税金及附加 | 96,428,924.86 | 314,041,960.95 | 233,828,884.22 | 164,222,484.23 |
| 销售费用 | 2,125,848,684.76 | 8,679,763,843.89 | 6,592,219,720.43 | 4,266,270,759.14 |
| 管理费用 | 973,133,319.14 | 4,283,257,270.64 | 3,144,563,560.08 | 2,064,431,733.81 |
| 研发费用 | 737,452,623.52 | 3,644,356,457.53 | 2,648,036,346.49 | 1,861,735,885.19 |
| 财务费用 | 277,182,559.81 | 1,110,518,015.23 | 854,564,650.13 | 588,833,274.33 |
| 其中:利息费用 | 329,525,596.08 | 1,431,914,682.08 | 1,067,876,593.66 | 709,545,120.01 |
| 其中:利息收入 | 76,419,034.23 | 373,210,305.16 | 279,711,179.34 | 188,969,456.09 |
| 加:公允价值变动收益 | -281,744,563.24 | -115,939,368.11 | -106,245,847.25 | -282,397,883.66 |
| 加:投资收益 | 1,281,381,740.69 | 2,104,607,405.87 | 1,498,762,805.9 | 1,061,766,335.39 |
| 资产处置收益 | -351,004.8 | 371,013,112.68 | 2,513,587.58 | 716,943.9 |
| 资产减值损失(新) | -10,549,160.99 | -96,569,884.79 | -40,946,606.35 | -20,173,454.3 |
| 信用减值损失(新) | -10,336,293.86 | -110,631,385.62 | -54,465,502.75 | -38,037,746.1 |
| 其他收益 | 90,389,864.88 | 422,939,687.33 | 258,894,140.64 | 153,479,541.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,358,771,228.34 | 4,245,103,909.31 | 3,107,588,817.82 | 1,929,286,791.65 |
| 加:营业外收入 | 3,344,414.93 | 58,893,032.43 | 34,567,912.8 | 28,856,541.36 |
| 减:营业外支出 | 14,573,671.26 | 134,715,262.02 | 70,590,845.22 | 26,942,539.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,347,541,972.01 | 4,169,281,679.72 | 3,071,565,885.4 | 1,931,200,793.34 |
| 减:所得税费用 | 405,975,695.16 | 656,841,294.72 | 553,048,247.94 | 381,468,816.23 |
| 六、净利润 | 941,566,276.85 | 3,512,440,385 | 2,518,517,637.46 | 1,549,731,977.11 |
| 持续经营净利润 | 941,566,276.85 | 3,512,440,385 | 2,518,517,637.46 | 1,549,731,977.11 |
| 归属于母公司股东的净利润 | 764,757,750.06 | 2,769,886,631.39 | 2,010,642,360.52 | 1,224,798,594.42 |
| 少数股东损益 | 176,808,526.79 | 742,553,753.61 | 507,875,276.94 | 324,933,382.69 |
| (一)基本每股收益 | 0.29 | 1.04 | 0.75 | 0.46 |
| (二)稀释每股收益 | 0.29 | 1.04 | 0.75 | 0.46 |
| 八、其他综合收益 | -110,471,546.95 | 43,142,250.33 | -213,927,299.31 | 112,419,919.18 |
| 归属于母公司股东的其他综合收益 | -112,742,402.26 | -16,229,211.38 | -177,247,663.14 | 96,538,158.48 |
| 九、综合收益总额 | 831,094,729.9 | 3,555,582,635.33 | 2,304,590,338.15 | 1,662,151,896.29 |
| 归属于母公司股东的综合收益总额 | 652,015,347.8 | 2,753,657,420.01 | 1,833,394,697.38 | 1,321,336,752.9 |
| 归属于少数股东的综合收益总额 | 179,079,382.1 | 801,925,215.32 | 471,195,640.77 | 340,815,143.39 |
| 公告日期 | 2025-04-30 | 2025-03-26 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |